{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:28:27Z","timestamp":1787160507208,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1124\/jpet.112.201665","type":"journal-article","created":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T08:15:58Z","timestamp":1359706558000},"page":"151-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"title":["Quantifying the Attenuation of the Ketamine Pharmacological Magnetic Resonance Imaging Response in Humans: A Validation Using Antipsychotic and Glutamatergic Agents"],"prefix":"10.1016","volume":"345","author":[{"given":"O.M.","family":"Doyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"De Simoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Brittain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.G.","family":"O\u2019Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. C.R.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.112.201665_bib1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/bja\/aem063","article-title":"Predictive performance of the Domino, Hijazi, and Clements models during low-dose target-controlled ketamine infusions in healthy volunteers","volume":"98","author":"Absalom","year":"2007","journal-title":"Br J Anaesth"},{"key":"10.1124\/jpet.112.201665_bib2","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1523\/JNEUROSCI.18-14-05545.1998","article-title":"Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine","volume":"18","author":"Adams","year":"1998","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.112.201665_bib3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0165-0173(99)00046-6","article-title":"Serotonin model of schizophrenia: emerging role of glutamate mechanisms","volume":"31","author":"Aghajanian","year":"2000","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1124\/jpet.112.201665_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrd2217","article-title":"How can drug discovery for psychiatric disorders be improved?","volume":"6","author":"Agid","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.112.201665_bib5","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/archpsyc.57.3.270","article-title":"Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists","volume":"57","author":"Anand","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"10.1124\/jpet.112.201665_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1124\/jpet.110.173880","article-title":"Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2\/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals","volume":"336","author":"Chin","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.112.201665_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/clpt.1987.193","article-title":"Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans","volume":"42","author":"Cohen","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.112.201665_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuroimage.2012.09.037","article-title":"Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers","volume":"64","author":"De Simoni","year":"2013","journal-title":"Neuroimage"},{"key":"10.1124\/jpet.112.201665_bib10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/archgenpsychiatry.2007.37","article-title":"Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study","volume":"65","author":"Deakin","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"10.1124\/jpet.112.201665_bib11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00213-007-0774-3","article-title":"Reversal of PCP-induced learning and memory deficits in the Morris\u2019 water maze by sertindole and other antipsychotics","volume":"193","author":"Didriksen","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.112.201665_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0006-8993(98)00926-3","article-title":"Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation","volume":"812","author":"Duncan","year":"1998","journal-title":"Brain Res"},{"key":"10.1124\/jpet.112.201665_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0022-3565(24)39197-9","article-title":"Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism","volume":"293","author":"Duncan","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.112.201665_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0006-8993(97)01390-5","article-title":"Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia","volume":"787","author":"Duncan","year":"1998","journal-title":"Brain Res"},{"key":"10.1124\/jpet.112.201665_bib15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/PL00005334","article-title":"Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4","volume":"359","author":"Fang","year":"1999","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/jpet.112.201665_bib16","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/0006-3223(95)00046-1","article-title":"Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?","volume":"38","author":"Farber","year":"1995","journal-title":"Biol Psychiatry"},{"issue":"1 Suppl 1","key":"10.1124\/jpet.112.201665_bib17","doi-asserted-by":"crossref","first-page":"19S","DOI":"10.1097\/00004714-199502001-00004","article-title":"Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients","volume":"15","author":"Farde","year":"1995","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/jpet.112.201665_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0014-2999(84)90404-7","article-title":"The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity","volume":"104","author":"Freeman","year":"1984","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.112.201665_bib19","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1038\/sj.npp.1301547","article-title":"Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine","volume":"33","author":"Gozzi","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.112.201665_bib20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.neuroscience.2010.02.057","article-title":"Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation","volume":"168","author":"Hackler","year":"2010","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.112.201665_bib21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/clpt.1993.146","article-title":"Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects","volume":"54","author":"Huang","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.112.201665_bib22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.mp.4001093","article-title":"NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia","volume":"7","author":"Kapur","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.1124\/jpet.112.201665_bib23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/1099","article-title":"Dopaminergic regulation of cerebral cortical microcirculation","volume":"1","author":"Krimer","year":"1998","journal-title":"Nat Neurosci"},{"key":"10.1124\/jpet.112.201665_bib24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s002130051049","article-title":"Interactive effects of subanesthetic ketamine and haloperidol in healthy humans","volume":"145","author":"Krystal","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.112.201665_bib25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1124\/jpet.112.201665_bib26","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/00000542-200405000-00006","article-title":"Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans","volume":"100","author":"L\u00e5ngsj\u00f6","year":"2004","journal-title":"Anesthesiology"},{"key":"10.1124\/jpet.112.201665_bib27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/0269881107077712","article-title":"Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?","volume":"21","author":"Large","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.112.201665_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-005-0020-9","article-title":"The potential role of lamotrigine in schizophrenia","volume":"181","author":"Large","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.112.201665_bib29","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0306-4522(02)00652-8","article-title":"Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268","volume":"117","author":"Lorrain","year":"2003","journal-title":"Neuroscience"},{"key":"10.1124\/jpet.112.201665_bib30","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1088\/0031-9155\/37\/7\/010","article-title":"A simplified formulation of the gamma variate function","volume":"37","author":"Madsen","year":"1992","journal-title":"Phys Med Biol"},{"key":"10.1124\/jpet.112.201665_bib31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1176\/appi.ajp.159.4.599","article-title":"Serotonin transporter distribution and density in the cerebral cortex of alcoholic and nonalcoholic comparison subjects: a whole-hemisphere autoradiography study","volume":"159","author":"Mantere","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.112.201665_bib32","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.neuroimage.2009.10.072","article-title":"Quantitative prediction of subjective pain intensity from whole-brain fMRI data using Gaussian processes","volume":"49","author":"Marquand","year":"2010","journal-title":"Neuroimage"},{"key":"10.1124\/jpet.112.201665_bib33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00213-010-2137-8","article-title":"The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment","volume":"213","author":"Meltzer","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.112.201665_bib34","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/sj.npp.1300479","article-title":"The serotonin 5-HT2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex","volume":"29","author":"Mirjana","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.112.201665_bib35","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.112.201665_bib36","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/sj.npp.1300342","article-title":"Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers","volume":"29","author":"Morgan","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.112.201665_bib37","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1176\/ajp.156.6.869","article-title":"Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients","volume":"156","author":"Nyberg","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.112.201665_bib38","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1017\/S1461145708009814","article-title":"Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude","volume":"12","author":"Oranje","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1124\/jpet.112.201665_bib39","doi-asserted-by":"crossref","unstructured":"Rasmussen CE, Williams CKI (2006) Gaussian Processes for Machine Learning, MIT Press, Cambridge, MA.","DOI":"10.7551\/mitpress\/3206.001.0001"},{"key":"10.1124\/jpet.112.201665_bib40","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0022-3565(25)13106-6","article-title":"Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade","volume":"277","author":"Schmidt","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.112.201665_bib41","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/mp.2011.171","article-title":"Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology","volume":"17","author":"Stone","year":"2012","journal-title":"Mol Psychiatry"},{"key":"10.1124\/jpet.112.201665_bib42","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1176\/appi.ajp.161.9.1620","article-title":"Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics","volume":"161","author":"Tauscher","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.112.201665_bib43","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/hbm.20035","article-title":"Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain","volume":"22","author":"Varn\u00e4s","year":"2004","journal-title":"Hum Brain Mapp"},{"key":"10.1124\/jpet.112.201665_bib44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0893-133X(98)00072-4","article-title":"M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats","volume":"20","author":"Varty","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.112.201665_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0924-977X(96)00039-9","article-title":"Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1124\/jpet.112.201665_bib46","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/(SICI)1099-1492(199706\/08)10:4\/5<237::AID-NBM475>3.0.CO;2-X","article-title":"Implementation of quantitative perfusion imaging techniques for functional brain mapping using pulsed arterial spin labeling","volume":"10","author":"Wong","year":"1997","journal-title":"NMR Biomed"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524185679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524185679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.112.201665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T12:20:45Z","timestamp":1739967645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524185679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0022356524185679"],"URL":"https:\/\/doi.org\/10.1124\/jpet.112.201665","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantifying the Attenuation of the Ketamine Pharmacological Magnetic Resonance Imaging Response in Humans: A Validation Using Antipsychotic and Glutamatergic Agents","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.112.201665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}